DUBLIN, October 23, 2017 /PRNewswire/ --

The "Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, and AgriBio including Test Price and Volume Forecasts with Executive and Consultant Guides 2018 to 2022" report has been added to Research and Markets' offering.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2022. The report includes detailed breakouts for 14 countries and 5 regions.

Germline? Somatic? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

Key Topics Covered:

i. Whole Genome Sequencing Market - Strategic Situation Analysis
ii. Guide for Executives, Marketing, Sales and Business Development Staff
iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition
1.1 Whole Genome Sequencing Definition In This Report
1.1.1 Exome Sequencing
1.1.2 Direct to Consumer
1.1.3 Pathogens and Tumors
1.1.4 Germline and Somatic
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing
1.5 Sizing the Genome - Not What You Think
1.5.1 Cost, Price and Genome Size, Pricing Practice

2. Market Overview
2.1 Market Participants Play Different Roles
2.1.1 Instrument Manufacturer
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Sequencing Labs
2.1.10 Audit body
2.2 Whole Genome Sequencing -Markets, Examples and Discussion
2.2.1 Direct to Consumer - Two Approaches
2.2.1.1 The New Age of Medical Information
2.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
2.2.1.3 Newborn and Prenatal - A Brave New World
2.2.1.4 DTC - How Many Segments?
2.2.2 Research Markets
2.2.2.1 Research Funding and Capital Expense
2.2.2.2 WGS Datasets Preferred
2.2.2.3 Existing research repurposed
2.2.2.4 Organism Wide Market
2.2.2.5 Service Suppliers Respond
2.2.3 Clinical - Understanding Germline and Somatic
2.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
2.2.4 Pathogen Testing
2.2.4.1 The Hepatitis C Story
2.2.4.2 Will the Microbiology Department Disappear?
2.2.5 AgriBio - Big Business
2.2.5.1 GMO is Here to Stay
2.2.5.2 WGS Benefits and Risks
2.2.5.3 The New Agriculture
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 Economies of Scale
2.3.3 Instrument Manufacturer Role
2.3.4 Healthcare Industry Impacts - Still Struggling
2.3.4.1 Can the Healthcare Industry Adapt?
2.3.4.2 Genetic Counselling as an Industry
2.3.4.3 WGES Adoption and Cannibalization
2.3.4.4 The Meaning of Grail
2.4 Profiles of Key Companies
2.4.1 Roche Molecular Diagnostics
2.4.2 Illumina
2.4.3 Grail
2.4.4 Complete Genomics - BGI
2.4.5 Qiagen
2.4.6 GE Global Research
2.4.7 BGI Genomics Co. Ltd.
2.4.8 Oxford Nanopore Technologies
2.4.9 Genomic Health
2.4.10 Pacific Biosciences
2.4.11 Siemens Healthcare
2.4.12 23 and Me
2.4.13 Ancestry.com
2.4.14 Bio-Rad
2.4.15 Thermo Fisher
2.4.16 Fabric Genomics
2.4.17 Centogene
2.4.18 Gene by Gene Ltd
2.4.19 Veritas Genetics
2.4.20 Dante Labs
2.4.21 Guardiome
2.4.22 Sure Genomics
2.4.23 Novogene
2.4.24 Helix
2.4.25 Genomics Personalized Health (GPH)
2.4.26 Sequencing.com
2.4.27 Omega Bioservices
2.4.28 ORIG3N
2.4.29 Human Longevity, Inc.
2.4.30 Invitae

3. Market Trends
3.1 Factors Driving Growth
3.1.1 Diagnostic Factors
3.1.2 Interpreting the Code Otherwise.
3.1.3 Changes in Agriculture.
3.1.4 Fertility Technology Comes of Age
3.1.5 Pathogen Challenges
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs.
3.2.3 Healthcare Cost Concerns Curtail Growth.
3.2.4 Wellness has a downside
3.2.5 GMO Opposition Movement
3.3 Sequencing Instrumentation
3.3.1 Instrumentation Tenacity.
3.3.2 Declining Cost of Instruments Changes Industry Structure.
3.3.3 LISTING of CURRENT INSTRUMENT SPECIFICATIONS.
3.3.4 Long Reads - Further Segmentation.
3.3.5 Linked Reads.
3.3.6 New Sequencing Technologies

4. WGES Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Future goal in UK is for every cancer patient to have his or her whole genome sequenced
4.3 Human Longevity Launches Whole Genome Product, MassMutual Partnerships
4.4 Influence of Whole Genome Sequencing growing
4.5 Rady Children's and Edico Genome Extend WGS Collaboration
4.6 $1500 to sequence newborns in China
4.7 Newborns to Get Whole Genome Sequencing
4.8 Eurofins Acquiring PerkinElmer's NTD Laboratory Services Business
4.9 Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
4.10 AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
4.11 The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics
4.12 Research Validates Preimplantation Genetic Diagnosis for Aneuploidy (PGD-A)
4.13 New Investments in Ancestry.com to Boost DNA Business
4.14 GHO Capital Announces Acquisition of DNA Diagnostics Center
4.15 PerkinElmer Launches Clinical Whole Genome Sequencing Services
4.16 WGS and AI help clinicians scale precision oncology
4.17 Veritas Genetics Buys Curoverse
4.18 Dante Labs Partners With Amazon UK for Special 349 Whole Genome Sequencing
4.19 Toolbox Genomics Launches Personalized Wellness App in Sequencing.com's Revolutionary App Market
4.20 CDC invests in WGS to help states respond to infectious disease threats
4.21 Factory contamination of medical device likely source of M. chimaera infection in patients in multiple countries
4.22 IBM Watson impresses in WGS brain tumour analysis
4.23 OneOme, Genome.One Partner to Offer Genetic Risk, PGx Service in Australia
4.24 WGS aids in Salmonella outbreak control
4.25 CombiMatrix In Merger Agreement with Invitae to be Acquired for $33 Million in Invitae Common Stock
4.53 Lifecode Receives CAP Accreditation, Discloses Funding
4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
4.60 Agena Bioscience Launches Smaller Format MassArray
4.62 The Journal of Molecular Diagnostics Publishes Special Article
4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
4.89 Floragenex, Sedia Biosciences Merge
4.90 Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health
4.91 Berry Genomics Seeks Public Listing in China Via Reverse Merger
4.92 Athletigen sees genetic testing as part of athletic training
4.93 AncestryDNA sees huge growth in demand for genetic testing
4.93 Phosphorus Raises $10 Million in Series A Funding to Build a Clinical Genomics Network . 233
4.94 NeoGenomics Q1 Revenues Jump on Genetic Test Volume Growth
4.95 Nevada Population Health Study to Offer Free 23andMe Genetic Tests to Community
4.96 Danaher to buy Cepheid in $4 billion deal to expand in diagnostics

5. Country Market Sizes - North America

6. Country Markets - Europe

7. Country Markets - Asia Pacific

8. Country Markets - Latin America, Africa & The Middle East

9. Global Market Summary

10. Vision of the Future of Whole Genome Sequencing

Appendices
I. United States Medicare System: January 2016 laboratory Fees Schedule - National Limit and Midpoint
II Methodology
II.1 Authors
II.2 Sources

For more information about this report visit https://www.researchandmarkets.com/research/m8p9pm/whole_genome_and

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets